Skip to main content

Advertisement

Fig. 1 | BMC Cancer

Fig. 1

From: Agreement between MRI and pathologic breast tumor size after neoadjuvant chemotherapy, and comparison with alternative tests: individual patient data meta-analysis

Fig. 1

Pathologic size (cm) of tumor “missed” by MRI for: a all patients with residual tumor (N = 243); and compared with b US (N = 123), c mammography (N = 78), and d clinical examination (N = 107). MRI = magnetic resonance imaging; N/A = not applicable; US = ultrasound. *Pathology and test(s) measure > 0.0 cm (i.e. residual tumor was not “missed” by MRI or alternative tests).

Back to article page